Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

G V Long, S S Tykodi, J G Schneider, C Garbe, G Gravis, M Rashford, S Agrawal, E Grigoryeva, A Bello, A Roy, L Rollin, X Zhao, G V Long, S S Tykodi, J G Schneider, C Garbe, G Gravis, M Rashford, S Agrawal, E Grigoryeva, A Bello, A Roy, L Rollin, X Zhao

Abstract

Background: A nivolumab monotherapy flat-dosing regimen of 480 mg every 4 weeks (Q4W) has been approved in several markets, including the United States, Canada, and European Union, as an alternative dosing regimen for several indications. Approvals of this Q4W regimen were based on population pharmacokinetic (PK) analyses, established flat exposure-response relationships, and clinical safety. The objective of this study was to compare the PK exposure of 480 mg Q4W with 3 mg/kg every 2 weeks (Q2W) and 240 mg Q2W using modeling and simulation, and to evaluate clinical safety of the Q4W regimen.

Patients and methods: Nivolumab PK exposure for the 480 mg Q4W schedule was simulated for 3817 patients across multiple tumor types and compared with those for the 3 mg/kg Q2W and 240 mg Q2W schedules. The safety profile of the Q4W schedule was assessed by analysis of clinical data from 61 patients who transitioned to nivolumab 480 mg Q4W from 3 mg/kg Q2W during four phase III clinical trials.

Results: Compared with 3 mg/kg Q2W, nivolumab 480 mg Q4W produced similar time-averaged concentration, approximately 16% lower trough concentration, and 45% higher peak concentration at steady state. The peak concentration for 480 mg Q4W was significantly lower than that of 10 mg/kg Q2W, a dose previously shown to have an acceptable tolerability and safety profile. Treatment-related adverse events (TRAEs) that started after transitioning from 3 mg/kg Q2W to 480 mg Q4W were reported in 14.8% of patients, with 1.6% of patients reporting grades 3-4 TRAEs. Pooled safety data for these patients are consistent with those for the 3 mg/kg Q2W schedules, and no new safety signals were identified.

Conclusions: The time-averaged steady-state exposure and safety profile of nivolumab 480 mg Q4W are consistent with that of 3 mg/kg Q2W across multiple tumor types. Nivolumab 480 mg Q4W represents a new dosing schedule option, and in addition to 240 mg Q2W, provides convenience and flexibility for patient care.

Clinical trial numbers: NCT01721772, NCT01668784, NCT01673867, NCT01642004.

Figures

Figure 1.
Figure 1.
Predicted exposure range for nivolumab flat dosing at 240 mg Q2W and 480 mg Q4W compared with 10 mg/kg Q2W (N = 3817). The boxes show the median, 25th, and 75th percentile per group. The whiskers extend to 1.5 times the interquartile range or the most extreme value (whichever is closer to the median value), and the values outside this range are not shown. Cavgss, time-averaged concentration at steady state; Cmaxss, peak concentration at steady state; GM, geometric mean; Q2W, every 2 weeks; Q4W, every 4 weeks.
Figure 2.
Figure 2.
Predicted geometric mean nivolumab concentration–time profiles of 240 mg Q2W and 240 mg Q2W (eight doses) followed by 480 mg Q4W over 1 year (N = 3817). Q2W, every 2 weeks; Q4W, every 4 weeks.

References

    1. OPDIVO (nivolumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb; August 2018.
    1. OPDIVO (nivolumab) [summary of product characteristics]. Uxbridge, UK: Bristol-Myers Squibb; July 2018.
    1. Agrawal S, Feng Y, Roy A. et al. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 2016; 72: 1–11.
    1. Topalian SL, Hodi FS, Brahmer JR. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26): 2443–2454.
    1. Bajaj G, Wang X, Agrawal S. et al. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol 2017; 6(1): 58–66.
    1. Zhao X, Suryawanshi S, Hruska M. et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol 2017; 28(8): 2002–2008.
    1. OPDIVO (nivolumab) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; July 2018.
    1. Zhao X, Ivaturi V, Gopalakrishnan M. et al. A model-based exposure–response (E–R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types. Cancer Res 2017; 77(13 Supplement): abstract CT101.
    1. Robert C, Long GV, Brady B. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372(4): 320–330.
    1. Motzer RJ, Escudier B, McDermott DF. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19): 1803–1813.
    1. Borghaei H, Paz-Ares L, Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17): 1627–1639.
    1. Brahmer J, Reckamp KL, Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373(2): 123–135.
    1. Feng Y, Wang X, Bajaj G. et al. Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. Clin Cancer Res 2017; 23(18): 5394–5405.
    1. Freshwater T, Kondic A, Ahamadi M. et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer 2017; 5(1): 43..
    1. Baverel PG, Dubois VFS, Jin CY. et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther 2018; 103(4): 631–642.
    1. Weber JS, Hodi FS, Wolchok JD. et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017; 35(7): 785–792.
    1. Hirsh V, Langleben A, Ayoub J. et al. Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma. Cancer 2001; 92(4): 830–835.
    1. Eckardt JR. Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 2004; 9(suppl_6): 25–32.
    1. Rossi A, Di Maio M.. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev Anticancer Ther 2016; 16(6): 653–660.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren